The expression of interleukin‐15 and interleukin‐17 in tears and orbital tissues of Graves ophthalmopathy patients

Chen, Qun

doi:10.1002/jcb.27916

Cited by 18 publications

(13 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of mentioned trials are very promising. What is more, also, IL-7, IL-8, IL-15, IL-16, and IL-17 are engaged in GO pathogenesis that suggests multifactorial background [29][30][31][32].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of IL-29 in Euthyroid Patients with Graves’ Orbitopathy: A Preliminary Study

Falkowski

Szczepanek‐Parulska

Sawicka‐Gutaj

et al. 2020

Mediators of Inflammation

View full text Add to dashboard Cite

Background. The most frequent cause of hyperthyroidism is Graves’ disease (GD). Orbitopathy is the most prevalent and recognizable extrathyroidal manifestation of Graves’ disease with unrevealed pathogenesis. Interleukin 29 (IL-29) is a relatively newly discovered inflammatory cytokine. Thus, the aim of this study was to evaluate the relationship between IL-29 and Graves’ orbitopathy (GO) in euthyroid patients. Methods. Thirty-one euthyroid patients with Graves’ disease and with active GO [clinical activity score CAS≥3/7], seventeen euthyroid patients with GD but without GO, and seventy-two healthy control subjects (CS) matched for age and gender were enrolled in the study. The following parameters were evaluated in every participant: thyroid-related hormones and autoantibodies and inflammatory markers (white blood cells, hsCRP). ELISA assay was applied to measure the concentration of IL-29. Results. We found higher level of IL-29 in GO group in comparison with CS [165 (133-747) vs. 62 (62-217) pg/mL, p<0.001]. Furthermore, participants in the subgroup with GD with GO as compared with GD without GO had higher concentration of IL-29 [165 (133-747) vs. 62 (62-558) pg/mL, p=0.031]. The ROC analysis for IL-29 revealed IL-29 cut-off of 105 pg/mL (sensitivity 1.000 and specificity 0.597) as the best value significantly indicating the presence of GO in GD [area under the ROC curve (AUC): 0.739, 95% confidence interval (CI): 0.646-0.833, p<0.001]. Conclusions. The present study revealed for the first time an elevated level of IL-29 in the serum of patients with GD and GO that might suggest its involvement in the pathogenesis of GD ocular complications.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of IL-29 in Euthyroid Patients with Graves’ Orbitopathy: A Preliminary Study

Falkowski

Szczepanek‐Parulska

Sawicka‐Gutaj

et al. 2020

Mediators of Inflammation

View full text Add to dashboard Cite

show abstract

“…Efficient blinking plays an important role in tear secretion by contraction of the muscle of Riolan, which is driven by blinking and then encourages meibomian gland secretions (Foulks & Bron, 2003; McMonnies, 2011) [ 36 , 37 ]. Incomplete blinking may result in meibomian stasis, obstruction and intraductal inflammation (Knop et al, 2011) [ 38 ].…”

Section: Discussionmentioning

confidence: 99%

Improvement of Ocular Surface Disease by Lateral Tarsoconjunctival Flap in Thyroid-Associated Orbitopathy Patients with Lid Retraction

Hsu

Hsieh

Chang

et al. 2022

JPM

View full text Add to dashboard Cite

There is a high incidence of ocular surface disease (OSD) in thyroid-associated orbitopathy (TAO) patients as a result of incomplete eyelid closure and chronic inflammatory eyelid status. This study was performed to evaluate the efficacy of a lateral tarsoconjunctival flap (LTF) in improving OSD in TAO patients from the perspective of correcting eyelid closures. As a study design, TAO patients were enrolled in this study to evaluate OSD perioperatively before they were scheduled for LTF surgery. Additional lid surgery was also recorded. The outcome was evaluated with perioperative OSD measurements and tear inflammatory mediators at baseline and one month and three months postoperatively. As a result, 42 patients (5 male, 37 female) underwent LTF surgery, and 13 patients received medial pretarsal support with collagen grafts. Eleven patients underwent blepharotomy, and 6 patients received Botox injections for upper lid retraction. The mean age of the participants was 46.4 years old, and the mean follow-up period was 10.6 months. Their clinical activity score (CAS) at the time of the operation was 2.1. Dry eye parameters, such as ocular surface disease index, tear breakup time, Schirmer’s I test score, and meibomian gland dropout were all significantly improved 3 months postoperatively. Tear osmolarity and inflammatory mediators in tear fluid, such as IL-6, IL-8, IL-18 and MCP-1, were also significantly improved after the procedures. After the surgery, all complications were mild and temporary. As a conclusion, LTF could provide TAO patients with both lid retraction correction and improvement of ocular surface disorders. Dry eye parameters significantly improved 3 months postoperatively. This method can serve as an alternative treatment option for lid correction in TAO patients.

show abstract

“…IL-17 expression is significantly correlated with thyroid-associated ophthalmopathy pathogenesis and development (Chen 2019). IL-17 can play dual functions in GD: a predisposing or protecting factor; for example, the portion of IL-17F/rs763780 genotypes in GD patients varied considerably from the control groups; the frequency of A allele of rs3819025 was lower in GD patients.…”

Section: Journal Of Molecular Endocrinologymentioning

confidence: 99%

Graves’ disease: introducing new genetic and epigenetic contributors

Razmara

Salehi

Aslani

et al. 2021

Journal of Molecular Endocrinology

View full text Add to dashboard Cite

Autoimmune thyroid disease (AITD) accounts for 90% of all thyroid diseases and affects 2-5% of the population with remarkable familial clustering. Among AITDs, Graves’ disease (GD) is a complex disease affecting thyroid function. Over the last two decades, case-control studies using cutting-edge gene sequencing techniques have detected various susceptible loci that may predispose individuals to GD. It has been presumed that all likely associated genes, variants, and polymorphisms might be responsible for 75-80% of the heritability of GD. As a result, there are implications concerning the potential contribution of environmental and epigenetic factors in the pathogenesis of GD, including its initiation, progression, and development. Numerous review studies have summarized the contribution of genetic factors in GD until now, but there are still some key questions and notions that have not been discussed concerning the interplay of genetic, epigenetic, and immunological factors. With this in mind, this review discusses some newly-identified loci and their potential roles in the pathogenicity of GD. This may lead to the identification of new, promising therapeutic targets. Here, we emphasized principles, listed all the reported disease-associated genes and polymorphisms, and also summarized the current understanding of the epigenetic basis of GD.

show abstract

The expression of interleukin‐15 and interleukin‐17 in tears and orbital tissues of Graves ophthalmopathy patients

Cited by 18 publications

References 21 publications

Evaluation of IL-29 in Euthyroid Patients with Graves’ Orbitopathy: A Preliminary Study

Evaluation of IL-29 in Euthyroid Patients with Graves’ Orbitopathy: A Preliminary Study

Improvement of Ocular Surface Disease by Lateral Tarsoconjunctival Flap in Thyroid-Associated Orbitopathy Patients with Lid Retraction

Graves’ disease: introducing new genetic and epigenetic contributors

Contact Info

Product

Resources

About